THE Indian government has ordered 660 million vaccine doses for August-December, its largest procurement, local media reported on Friday (16).
State authorities and health experts in the country have recently warned that shortages could leave millions vulnerable if coronavirus infections surge again.
On Friday, India reported 38,949 new coronavirus cases over the last 24 hours, health ministry data showed, taking the nationwide tally above 31 million. Total fatalities were 412,531.
The federal government aims to inoculate all of the country's estimated 944 million adults by December, target health experts have said is ambitious.
Currently, only 8 per cent of that number is vaccinated with the mandatory two doses.
Several states have reported vaccine shortages, with many inoculation centres shut and people having to wait for long hours at others for their shot.
The government has now ordered 375m more doses of AstraZeneca's locally produced Covishield and 285m doses of Bharat Biotech's homegrown Covaxin, the Economic Times newspaper reported, citing sources.
The health ministry did not immediately respond to a Reuters request for comment.
The Serum Institute of India, which manufactures Covishield, has raised monthly production to about 100 million doses.
The government says Bharat Biotech's monthly output will jump to as much as 70m doses in July/August, from about 10m doses in April. Production could rise further to nearly 100 million by September, it says.
Bharat Biotech, which has been struggling to raise the output of its vaccine, did not respond to a request for an update on its production plans.
"I expect the vaccine shortage to continue and as per the planned vaccine supply, it appears that the daily average for the whole of July will stay below 4m," said Rijo John, health economist and a professor at the Rajagiri College of Social Sciences in the southern city of Kochi.
After a record 9.1m doses were administered on June 21, fewer than 4m doses per day have since been given on an average this month.
A full rollout of Russia's Sputnik V vaccine in India has also been delayed due to a lack of imported supplies. Commercial production of the vaccine in India, however, could begin soon.
India's daily Covid-19 cases have dropped to nearly two-month lows, the country remains the second-highest globally in terms of daily infections.
